Compare

BPC-157 (Oral) vs IGF-1 LR3

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

BPC-157 (Oral)

752 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 56% · Mixed 28% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite control
15
Energy
124
Mood
161
Focus
188
Sleep quality
124

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

GI discomfort
111
Dizziness
24
Fatigue
126
Nausea
183
Water retention
123

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 200–400 mcg

Reports span 10–600 mcg

10–25
2
25–50
5
50–100
10
100–200
16
200–400
17
400–600
10

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing36stacking19side effects22bpc-157 (oral)10

How repeat users are trending

Among repeat reporters, 66% said they felt similar to their last entry, 42% more positive, and 16% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 16 days · Based on 165 repeat reporters

IGF-1 LR3

764 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 68% · Mixed 16% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-117
Focus
-162
Sleep quality
-145
Lean mass
-166
Joint comfort
-101

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-21
Nausea
-83
Water retention
0
Appetite loss
10
Injection site reaction
-101

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
2
50–100
13
100–200
22
200–400
11
400–600
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing48stacking31side effects34igf-1 lr322

How repeat users are trending

Among repeat reporters, 63% said they felt similar to their last entry, 42% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 168 repeat reporters

Sources (8)

Published sources linked on the BPC-157 (Oral) and IGF-1 LR3 wiki pages.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review)

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  3. PubMed

    Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions

    Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011

    Source
    Wiki study page →
  4. PubMed

    Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions

    Tlak Gajger I, Ribarić J, Smodiš Škerl M, et al. Journal of veterinary pharmacology and therapeutics. 2018

    Source
    Wiki study page →
  5. PubMed

    Insulin-like growth factor-I and its binding proteins in sport and exercise medicine

    Baxter RC. Endocr Rev. 2011

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    IGF-1 LR3 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. PubMed

    Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice

    Engel MG, Narayan S, Cui MH, et al. Journal of Alzheimer's disease : JAD. 2025

    Source
    Wiki study page →
  8. PubMed

    Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration

    Yavuz E, Sağır MS, Ercan A, et al. International journal of biological macromolecules. 2025

    Source
    Wiki study page →